Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001104659-20-095581
Filing Date
2020-08-14
Accepted
2020-08-14 16:32:03
Documents
8
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13D a20-27571_1sc13d.htm SC 13D 221324
2 EX-99.1 a20-27571_1ex99d1.htm EX-99.1 19751
3 EX-99.2 a20-27571_1ex99d2.htm EX-99.2 291103
4 EX-99.4 a20-27571_1ex99d4.htm EX-99.4 124277
5 EX-99.5 a20-27571_1ex99d5.htm EX-99.5 24457
6 EX-99.6 a20-27571_1ex99d6.htm EX-99.6 28965
7 GRAPHIC g275711moi001.gif GRAPHIC 1341
8 GRAPHIC g275711moi002.jpg GRAPHIC 631
  Complete submission text file 0001104659-20-095581.txt   714523
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Filed by) CIK: 0001030617 (see all company filings)

Type: SC 13D

Mailing Address 209 PERRY PARKWAY SUITE 13 GAITHERSBURG MD 20877
Business Address 209 PERRY PARKWAY SUITE 13 GAITHERSBURG MD 20877 (301) 825 5320
Cellular Biomedicine Group, Inc. (Subject) CIK: 0001378624 (see all company filings)

EIN.: 861032927 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-82437 | Film No.: 201105631
SIC: 2836 Biological Products, (No Diagnostic Substances)